The immunoscore, based on the quantification of the CD3+ and CD8+ tumor-infiltrating lymphocytes at the invasive margin and at the core of the carcinoma, has been proven to be more reliable than tumor-node-metastasis (TNM) staging, as a prognostic marker in patients with CRC [29,30]. This evidence concerns the gene CD8A and neoplasm.